Hepatoprotective effects of IL-22 were found in a primary Plasmodium chabaudi infection model,[13] but IL-22
did not show any protective effects against liver lesions CHIR-99021 manufacturer infected by the parasite Toxoplasma gondii and Mycobacterium avium.[24] In addition, in a model of hepatitis B virus (HBV) replication in HBV transgenic mice, blocking IL-22 with a neutralizing antibody ameliorated liver damage by reducing chemokine expression on hepatocytes, and subsequently preventing hepatic recruitment of inflammatory cells, suggesting that IL-22 may contribute to the pathogenesis of HBV-mediated liver inflammation and injury.[25] The liver has great regenerative ability after injury induced by hepatotoxins, infections, or loss of tissues. Under most conditions, the liver can regain its original mass through the proliferation of mature healthy hepatocytes. However, when mature hepatocytes are unable to properly proliferate to restore damaged liver during severe or chronic liver injury, LPC-mediated liver repair
will be utilized to compensate liver functions.[26-31] The beneficial effects of IL-22 on mature hepatocyte survival and proliferation have been well documented.[10-20] Recent studies from our lab suggest that IL-22 also promotes LPC growth in patients with chronic selleck chemical viral hepatitis and in mice challenged by feeding a 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) diet or a choline-deficient, ethionine-supplemented diet.[21] Increased IL-22 expression was observed in patients with chronic HBV or HCV infection.[19, 24, 32] IL-22 expression correlated with LPC proliferation in HBV patients, which implies that IL-22 may promote LPC growth in those patients.[21] IL-22TG mice with IL-22
overexpression in the liver were not associated with increased LPC number under a normal chow, but showed significant higher LPC proliferation rate and total LPC number compared with wild-type (WT) mice after being fed a DDC diet.[21] This suggests that IL-22 alone does not initiate LPC activation, but it can promote existing LPC proliferation in vivo in the DDC model. The LPCs that were isolated from the DDC-fed mice expressed medchemexpress high levels of IL-22R1 and IL-10R2. This is not surprising because IL-22R1 is known to be expressed on epithelial cells, and LPCs are the progenitor cells for liver epithelial cells, including hepatocytes and biliary epithelial cells. In vitro treatment with IL-22 promotes proliferation of primary LPCs from the DDC-fed mice or proliferation of the LPC cell line, BMOL (bipotential mouse oval liver) cells,[21] suggesting that IL-22 directly stimulates LPC proliferation. It has previously been well documented that STAT3 activation mediates many functions of IL-22 in hepatocytes. Recently, we have provided several lines of evidence that suggest that STAT3 also plays an important role in IL-22-mediated stimulation of LPC proliferation.
No related posts.